Faron Pharmaceuticals OY (FARN), the Finnish clinical-stage biopharmaceutical company, has received a major shareholding notification from Heights Capital Management, Inc., a San Francisco-based investment manager, disclosing a combined voting rights position of 17.34% as of 12 November 2026. The holding is split between shares and convertible bonds, with the total position falling from a previously notified level of 19.96%. The notification was filed with Faron on 13 November 2026 and lodged via TR-1 form in accordance with UK Disclosure and Transparency Rules, reflecting an acquisition or disposal of voting rights.

Key Points

  • Faron Pharmaceuticals OY (FARN) — Finnish biopharmaceutical company listed on AIM
  • Heights Capital Management, Inc. and CVI Investments, Inc. disclosed a combined 17.34% voting rights position, down from 19.96% at the previous notification
  • Total voting rights held amount to 43,975,360; threshold crossing date was 12 November 2026
  • Investors should watch whether the position continues to decline and how convertible bond maturities in February 2027 and February 2028 affect the holding

Heights Capital and CVI Investments Reduce Combined Position in Faron to 17.34%

According to the TR-1 notification, Heights Capital Management, Inc., acting through its controlled entity CVI Investments, Inc. — registered in the Cayman Islands — held a total of 43,975,360 voting rights in Faron Pharmaceuticals OY as of 12 November 2026. This represents a combined position of 17.34%, comprising 7.99% from shares held directly and indirectly, and 10.16% through financial instruments. The previous notification recorded a higher combined position of 19.96%, indicating a net reduction in the overall stake, consistent with an acquisition or disposal of voting rights as cited in the filing.

Convertible Bonds Maturing in 2027 and 2028 Account for 10.16% of Faron's Voting Rights

The financial instruments component of the holding consists entirely of two convertible bonds. The first, maturing on 8 February 2027, carries the right to acquire 10,080,000 voting rights, equating to 3.97% of Faron's total. The second, maturing on 12 February 2028, may convert into 15,680,000 voting rights, representing 6.18%. Both instruments are exercisable at any time until their respective maturity dates. Together they form the 25,760,000 voting rights recorded under Section 8.B.1 of the notification. Investors may be watching how these conversion rights are exercised as the nearer maturity date approaches in early 2027.

Faron Pharmaceuticals' Share Structure and the Regulatory Context of the Disclosure

Faron Pharmaceuticals OY is classified as a non-UK issuer under the TR-1 framework, though the notification was completed in London on 13 November 2026 and filed in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules. The company operates as a clinical-stage biopharmaceutical group focused on novel oncology and inflammatory disease treatments. The direct shareholding component stands at 18,215,360 voting rights, with an additional 25,760,000 held indirectly, confirming Heights Capital Management as the controlling entity over CVI Investments for the purposes of this disclosure.